Navigation Links
Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
Date:12/4/2013

ists of surgical removal of the tumor bulk, followed by radiation and chemotherapy with temozolomide.  KX02 has demonstrated the ability to clear gliomas in a well-established animal model and also prevent tumor recurrence in these animals and we are excited to move this novel compound into the clinical setting.   We have worked diligently with clinical sites to establish the trial protocols and expect to initiate a Phase 1 trial imminently."

XiangXue Pharmaceuticals is Kinex's collaborative development partner for KX02 in China and has an exclusive license from Kinex for this territory. Mr. YongHui Wang, Chairman and CEO of XiangXue Pharmaceuticals added, "Kinex has been an excellent collaborative partner.  Their ability to develop novel drugs and work closely with regulatory agencies continues to impress us and we are very pleased that the FDA has granted Orphan Drug Status for KX02. Glioblastoma is an aggressive cancer with few treatment alternatives.  In fact, the average patient with malignant glioblastoma has a life expectancy of less than 12 months once they are diagnosed with the disease.  I am hopeful, based on promising animal studies, that KX02 can provide a new treatment option for this devastating disease. XiangXue is developing our IND application for the Chinese State FDA and we are planning to initiate KX02 trials for Chinese patients with brain tumor patients in 2014."

About orphan drug status:
FDA Orphan Drug Designation is designed to encourage the development of drugs involved in the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in the United States. This designation will provide Kinex with seven years of marketing exclusivity for KX02 in the treatment of glioblastoma patients if KX02 is approved for this indication. Orphan drug designation also affords the potential to ob
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
2. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
3. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
4. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
5. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
6. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
7. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
8. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
9. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
10. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
11. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
(Date:4/17/2015)... CVS Health Corporation (NYSE: CVS ) ... 1, 2015, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call will ... the CVS Health website for all interested parties. To ... will be archived and available on the web site ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... , DES MOINES, Iowa, Oct. 12 Briggs, a ... reduce operating costs in the home care market, today ... mandated by the Centers for Medicare & Medicaid Services ... proprietary documentation for all OASIS assessment forms as well ...
... 12 The University of Kansas Hospital has deployed ... provide physicians, nurses, and pharmacy staff in its neonatal ... and reference information. , The University of ... specializes in heart disease, cancer treatment and prevention, neurology, ...
Cached Medicine Technology:Regulatory Leader in OASIS Documentation Introduces OASIS-C Products 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 3
(Date:4/17/2015)... Riviera Magazine has featured board ... the Gallery of Cosmetic Surgery in Newport Beach, California ... The publication focused on his expertise in the lower ... eyelid surgery, laser resurfacing and rhinoplasty. , Dr. Sadati’s ... resulted in thousands of satisfied patients across the globe. ...
(Date:4/17/2015)... 17, 2015 From the day Dr. Todd ... Texas non-profit organization has empowered young people to create meaningful ... bring fresh water and the Gospel to all of ... Between March 17 and 27, students, faculty and staff raised ... with fresh water and the Good News of Jesus. ...
(Date:4/17/2015)... 17, 2015 Enthusiasts of gourmet cuisine and ... April 25, 2015. The event will be held in the ... (201 Monroe Ave NW, Grand Rapids, MI 49503) and will ... Michigan area. Patrons are encouraged to savor the food and ... , This year’s event will feature seven chefs, including:, ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Testosterone ... this class of prescription medications increases the likelihood ... stroke or other life-threatening cardiovascular event continue to ... District Court, Northern District of Illinois. According to ... Judicial Panel on Multidistrict Litigation (JPML) on April ...
(Date:4/17/2015)... Francisco, CA (PRWEB) April 17, 2015 The American ... House event and Free Application Day on April 29. The event ... ACTCM Pioneer Square, located at 555 DeHaro St. in San Francisco, ... 11 a.m. – Check in at the DeHaro campus (room F), ... – Tour of campus, Noon – Light lunch with current students, ...
Breaking Medicine News(10 mins):Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2
... By Serena Gordon HealthDay Reporter , TUESDAY, Oct. ... an advance directive may raise the odds that you,ll receive ... care, a new study indicates. An advance directive, sometimes ... your wishes for the type of care you would like ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, Oct. 4 ... develop breast cancer tend to have more advanced cases than women ... statistics are adjusted for factors such as age, men with breast ... are. The findings shed light on a rare disease in ...
... News) --, People may be learning while they sleep, dramatically ... Although the effects on memory vary greatly and ... findings reinforce the need for a good night,s sleep -- ... the U.S. National Sleep Foundation. "We speculate that we ...
... , TUESDAY, Oct. 4 (HealthDay News) -- ... a recurrence of the disease and improve their overall ... The group pointed out that physical activity has many ... reduced fatigue and improved mood. To help mark ...
... Salamon HealthDay Reporter , TUESDAY, Oct. 4 (HealthDay ... of nature versus nurture, it appears that kids unlucky enough ... sunnier outlooks when they,re parented in a warm, positive manner. ... through 15 with a gene variation predisposing them to lower ...
... at Virginia G. Piper Cancer Center Clinical Trials at ... participate in a clinical trial to determine the safety, ... combination consisting of a standard drug called gemcitabine and ... cancer. The results of this study, ...
Cached Medicine News:Health News:Advance Directives Might Curb Cost of End-of-Life Care 2Health News:Advance Directives Might Curb Cost of End-of-Life Care 3Health News:Breast Cancer Appears Less Deadly for Men Than Women 2Health News:Exercise Tips for Breast Cancer Survivors 2Health News:Happy Kids a Product of Genes, Parenting, Study Finds 2Health News:Happy Kids a Product of Genes, Parenting, Study Finds 3Health News:TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients 2
... is an endoscopic urethral implant for ... Upon implantation, the Tegress™ Implant solution ... in a Dimethyl Sulfoxide (DMSO) carrier ... reinforces the integrity of the urethras ...
... (VZ) test system is intended ... detection of VZ IgG antibody ... indirect fluorescent antibody (IFA) technique. ... confirm a recent infection or ...
... Captia™ Varicella-Zoster Virus (VZV) IgM ... intended for the detection of ... in human serum as an ... primary infection or reactivation. For ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: